|
FY2024
12 months to Dec 31, 2025
|
FY2023
12 months to Dec 31, 2024
|
FY2022
12 months to Dec 31, 2023
|
FY2021
12 months to Dec 31, 2022
|
FY2020
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Operating expenses: | |||||
| Acquired in-process research and development | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Change in fair value of warrant liability /Series A warrant and pre-funded warrant expense | |||||
| Other income, net | |||||
| Net income (loss) | |||||
| Net income (loss) attributable to common stockholders, basic | |||||
| Net income (loss) attributable to common stockholders, diluted | |||||
| Weighted-average shares of common stock outstanding, basic (in shares) | |||||
| Net income (loss) per share of common stock, basic (in dollars per share) | |||||
| Weighted-average shares of common stock outstanding, diluted (in shares) | |||||
| Net income (loss) per share of common stock, diluted (in dollars per share) | |||||
| Net income (loss) attributable to Series C Preferred stockholders, basic | |||||
| Net income (loss) attributable to Series C Preferred stockholders, diluted | |||||
| Weighted-average shares of Series C Preferred outstanding, basic (in shares) | |||||
| Weighted-average shares of Series C Preferred outstanding, diluted (in shares) | |||||
| Net income (loss) per share of Series C Preferred, basic (in dollars per share) | |||||
| Net income (loss) per share of Series C Preferred, diluted (in dollars per share) |
Loading...